AR096721A1 - Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos - Google Patents
Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidosInfo
- Publication number
- AR096721A1 AR096721A1 ARP140102388A ARP140102388A AR096721A1 AR 096721 A1 AR096721 A1 AR 096721A1 AR P140102388 A ARP140102388 A AR P140102388A AR P140102388 A ARP140102388 A AR P140102388A AR 096721 A1 AR096721 A1 AR 096721A1
- Authority
- AR
- Argentina
- Prior art keywords
- carboxamida
- tetrahydrocarbazol
- carbazol
- substituted compounds
- diseases
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- XKLNOVWDVMWTOB-UHFFFAOYSA-N 2,3,4,9-tetrahydro-1h-carbazole Chemical compound N1C2=CC=CC=C2C2=C1CCCC2 XKLNOVWDVMWTOB-UHFFFAOYSA-N 0.000 title 1
- GZSUIHUAFPHZSU-UHFFFAOYSA-N 9-ethyl-2,3-dihydro-1h-carbazol-4-one Chemical compound C12=CC=CC=C2N(CC)C2=C1C(=O)CCC2 GZSUIHUAFPHZSU-UHFFFAOYSA-N 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361839141P | 2013-06-25 | 2013-06-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR096721A1 true AR096721A1 (es) | 2016-01-27 |
Family
ID=51210830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140102388A AR096721A1 (es) | 2013-06-25 | 2014-06-24 | Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos |
Country Status (31)
| Country | Link |
|---|---|
| US (6) | US9334290B2 (enExample) |
| EP (1) | EP3013814B1 (enExample) |
| JP (1) | JP6353529B2 (enExample) |
| KR (1) | KR102346508B1 (enExample) |
| CN (1) | CN105358546B (enExample) |
| AR (1) | AR096721A1 (enExample) |
| AU (1) | AU2014302548B2 (enExample) |
| BR (1) | BR112015030723A8 (enExample) |
| CA (1) | CA2916500A1 (enExample) |
| CL (1) | CL2015003635A1 (enExample) |
| CY (1) | CY1119371T1 (enExample) |
| DK (1) | DK3013814T3 (enExample) |
| EA (1) | EA026729B1 (enExample) |
| ES (1) | ES2636652T3 (enExample) |
| HR (1) | HRP20171031T1 (enExample) |
| HU (1) | HUE034460T2 (enExample) |
| IL (1) | IL243296B (enExample) |
| LT (1) | LT3013814T (enExample) |
| MA (1) | MA38648B1 (enExample) |
| MY (1) | MY176631A (enExample) |
| PE (1) | PE20160519A1 (enExample) |
| PH (1) | PH12015502630A1 (enExample) |
| PL (1) | PL3013814T3 (enExample) |
| PT (1) | PT3013814T (enExample) |
| RS (1) | RS56371B1 (enExample) |
| SI (1) | SI3013814T1 (enExample) |
| SM (1) | SMT201700422T1 (enExample) |
| TN (1) | TN2015000529A1 (enExample) |
| TW (1) | TWI648272B (enExample) |
| UY (1) | UY35625A (enExample) |
| WO (1) | WO2014210085A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2015016771A (es) | 2013-06-25 | 2016-03-31 | Squibb Bristol Myers Co | Compuestos de carbazol carboxamida utiles como inhibidores de cinasa. |
| AR102426A1 (es) | 2014-10-24 | 2017-03-01 | Bristol Myers Squibb Co | Compuestos de indolcarboxamida como inhibidores de btk |
| EA031614B1 (ru) | 2014-10-24 | 2019-01-31 | Бристол-Майерс Сквибб Компани | Трициклические атропоизомерные соединения |
| PE20171239A1 (es) * | 2014-10-24 | 2017-08-24 | Bristol Myers Squibb Co | Derivados de carbazol |
| CA3029482A1 (en) | 2016-07-01 | 2018-01-04 | Brio Device Llc | Intubation stylet with video feed |
| CN108101905A (zh) * | 2016-11-24 | 2018-06-01 | 中国科学院上海药物研究所 | 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途 |
| MA46995A (fr) | 2016-12-03 | 2019-10-09 | Acerta Pharma Bv | Méthodes et compositions pour l'utilisation de lymphocytes t thérapeutiques en association avec des inhibiteurs de kinase |
| JP7028889B2 (ja) * | 2016-12-20 | 2022-03-02 | ブリストル－マイヤーズ スクイブ カンパニー | テトラヒドロカルバゾールカルボキサミド化合物の製造方法 |
| EP3789040A4 (en) | 2018-04-27 | 2022-03-09 | ONO Pharmaceutical Co., Ltd. | PREVENTIVE AND/OR THERAPEUTIC AGENT FOR AUTOIMMUNE DISEASES WITH A COMPOUND WITH BTK INHIBITING ACTIVITY AS AN INGREDIENT |
| CA3224985C (en) | 2018-07-31 | 2025-11-18 | Loxo Oncology, Inc. | SPRAY-DRIED DISPERSIONS, FORMULATIONS AND POLYMORPHIES OF (S)-5-AMINO-3-(4-((5-FLUORO-2-METHOXYBENZAMIDO)METHYL)PHENYL)(1,1,1-TRIFLUOROPROPANE-2-YL)-1H-PYRAZOLE-4-CARBOXAMIDE |
| US20240100172A1 (en) | 2020-12-21 | 2024-03-28 | Hangzhou Jijing Pharmaceutical Technology Limited | Methods and compounds for targeted autophagy |
| WO2022212893A1 (en) | 2021-04-02 | 2022-10-06 | Biogen Ma Inc. | Combination treatment methods of multiple sclerosis |
| AU2023220628A1 (en) * | 2022-02-15 | 2024-05-23 | F. Hoffmann-La Roche Ag | Processes for the preparation of 1,2,3,5,6,7-hexahydro-s-indacene derivatives |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4200750A (en) | 1977-01-07 | 1980-04-29 | Westwood Pharmaceuticals Inc. | 4-Substituted imidazo [1,2-a]quinoxalines |
| CA2140722A1 (en) | 1994-01-24 | 1995-07-25 | Joseph A. Jakubowski | Beta-carboline thromboxane synthase inhibitors |
| WO2005014599A1 (en) | 2003-06-04 | 2005-02-17 | Cellular Genomics, Inc. | Imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of bruton’s tyrosine kinase by such compounds |
| WO2005005429A1 (en) | 2003-06-30 | 2005-01-20 | Cellular Genomics, Inc. | Certain heterocyclic substituted imidazo[1,2-a]pyrazin-8-ylamines and methods of inhibition of bruton’s tyrosine kinase by such compounds |
| WO2005047290A2 (en) | 2003-11-11 | 2005-05-26 | Cellular Genomics Inc. | Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors |
| DE602005023333D1 (de) | 2004-10-15 | 2010-10-14 | Takeda Pharmaceutical | Kinaseinhibitoren |
| EP1812442A2 (en) | 2004-11-10 | 2007-08-01 | CGI Pharmaceuticals, Inc. | Imidazo[1,2-a]pyrazin-8-ylamines useful as modulators of kinase activity |
| AP2334A (en) | 2004-12-17 | 2011-12-06 | Glenmark Pharmaceuticals Sa | Novel heterocyclic compounds useful for the treatment of inflamatory and allergic disorders. |
| WO2006099075A2 (en) | 2005-03-10 | 2006-09-21 | Cgi Pharmaceuticals, Inc. | Certain substituted amides, method of making, and method of use thereof |
| EP1924557A2 (en) * | 2005-09-16 | 2008-05-28 | Serenex, Inc. | Carbazole derivatives |
| US20070078136A1 (en) | 2005-09-22 | 2007-04-05 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| US7723336B2 (en) | 2005-09-22 | 2010-05-25 | Bristol-Myers Squibb Company | Fused heterocyclic compounds useful as kinase modulators |
| ES2390135T3 (es) | 2005-11-22 | 2012-11-06 | Merck Sharp & Dohme Corp. | Compuestos tricíclicos útiles como inhibidores de quinasas |
| RU2009113585A (ru) | 2006-09-11 | 2010-10-20 | Матрикс Лэборетериз Лтд. (In) | Производные дибензофурана в качестве ингибиторов pde-4 и pde-10 |
| JP2010502751A (ja) | 2006-09-11 | 2010-01-28 | シージーアイ ファーマシューティカルズ，インコーポレイティド | キナーゼ阻害物質、およびキナーゼ阻害物質の使用および同定方法 |
| US20090062251A1 (en) | 2007-08-17 | 2009-03-05 | Astrazeneca Ab | Novel Compounds 002 |
| CA2707491A1 (en) | 2007-12-13 | 2009-06-18 | Merck Sharp & Dohme Corp. | Inhibitors of janus kinases |
| LT2247558T (lt) | 2008-02-14 | 2022-04-11 | Eli Lilly And Company | Nauji vizualizavimo agentai neurologinės disfunkcijos aptikimui |
| GB0809360D0 (en) | 2008-05-22 | 2008-07-02 | Isis Innovation | Calcium modulation |
| EP2151441A1 (en) | 2008-08-06 | 2010-02-10 | Julius-Maximilians-Universität Würzburg | Beta-carbolin-derivates as substrates for an enzyme |
| ES2443948T3 (es) * | 2008-12-19 | 2014-02-21 | Bristol-Myers Squibb Company | Compuestos de carbazol carboxamida útiles como inhibidores de quinasas |
| CN101475571B (zh) | 2009-01-21 | 2011-06-22 | 中国药科大学 | β-咔啉类细胞周期蛋白依赖性激酶2抑制剂及其用途 |
| US8242260B2 (en) | 2009-08-28 | 2012-08-14 | Novartis Ag | Compounds and compositions as protein kinase inhibitors |
| WO2011116867A1 (de) | 2010-03-26 | 2011-09-29 | Merck Patent Gmbh | Benzonaphthyridinamine als autotaxin-inhibitoren |
| US8685969B2 (en) * | 2010-06-16 | 2014-04-01 | Bristol-Myers Squibb Company | Carboline carboxamide compounds useful as kinase inhibitors |
| EP2455378A1 (en) | 2010-11-03 | 2012-05-23 | Philip Morris Products S.A. | Carbazole and carboline derivatives, and preparation and therapeutic applications thereof |
| CN103429595B (zh) | 2010-11-15 | 2015-10-21 | Viiv保健英国有限公司 | Hiv复制的抑制剂 |
| JP5859640B2 (ja) | 2011-05-17 | 2016-02-10 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ブルトンチロシンキナーゼ阻害剤 |
| WO2013054185A1 (en) | 2011-10-13 | 2013-04-18 | Pfizer, Inc. | Pyrimidine and pyridine derivatives useful in therapy |
-
2014
- 2014-06-24 TW TW103121681A patent/TWI648272B/zh not_active IP Right Cessation
- 2014-06-24 AR ARP140102388A patent/AR096721A1/es unknown
- 2014-06-24 UY UY0001035625A patent/UY35625A/es unknown
- 2014-06-25 TN TN2015000529A patent/TN2015000529A1/en unknown
- 2014-06-25 DK DK14740094.9T patent/DK3013814T3/en active
- 2014-06-25 PL PL14740094T patent/PL3013814T3/pl unknown
- 2014-06-25 ES ES14740094.9T patent/ES2636652T3/es active Active
- 2014-06-25 EP EP14740094.9A patent/EP3013814B1/en active Active
- 2014-06-25 RS RS20170904A patent/RS56371B1/sr unknown
- 2014-06-25 HU HUE14740094A patent/HUE034460T2/en unknown
- 2014-06-25 JP JP2016523869A patent/JP6353529B2/ja not_active Expired - Fee Related
- 2014-06-25 HR HRP20171031TT patent/HRP20171031T1/hr unknown
- 2014-06-25 CA CA2916500A patent/CA2916500A1/en not_active Abandoned
- 2014-06-25 EA EA201592287A patent/EA026729B1/ru not_active IP Right Cessation
- 2014-06-25 MY MYPI2015704738A patent/MY176631A/en unknown
- 2014-06-25 SM SM20170422T patent/SMT201700422T1/it unknown
- 2014-06-25 MA MA38648A patent/MA38648B1/fr unknown
- 2014-06-25 WO PCT/US2014/043978 patent/WO2014210085A1/en not_active Ceased
- 2014-06-25 AU AU2014302548A patent/AU2014302548B2/en not_active Ceased
- 2014-06-25 PT PT147400949T patent/PT3013814T/pt unknown
- 2014-06-25 CN CN201480035611.8A patent/CN105358546B/zh not_active Expired - Fee Related
- 2014-06-25 KR KR1020167001632A patent/KR102346508B1/ko not_active Expired - Fee Related
- 2014-06-25 PE PE2015002665A patent/PE20160519A1/es active IP Right Grant
- 2014-06-25 LT LTEP14740094.9T patent/LT3013814T/lt unknown
- 2014-06-25 BR BR112015030723A patent/BR112015030723A8/pt not_active Application Discontinuation
- 2014-06-25 US US14/314,602 patent/US9334290B2/en active Active
- 2014-06-25 SI SI201430268T patent/SI3013814T1/sl unknown
-
2015
- 2015-11-26 PH PH12015502630A patent/PH12015502630A1/en unknown
- 2015-12-15 CL CL2015003635A patent/CL2015003635A1/es unknown
- 2015-12-22 IL IL243296A patent/IL243296B/en active IP Right Grant
-
2016
- 2016-03-11 US US15/067,915 patent/US20160194338A1/en not_active Abandoned
-
2017
- 2017-06-16 US US15/625,417 patent/US9850258B2/en active Active
- 2017-09-06 CY CY20171100943T patent/CY1119371T1/el unknown
- 2017-11-10 US US15/809,437 patent/US10106559B2/en active Active
-
2018
- 2018-09-25 US US16/140,750 patent/US10435415B2/en active Active
-
2019
- 2019-08-22 US US16/547,675 patent/US20190382416A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201790766A1 (ru) | Новые соединения метилпиперидина, подходящие для ингибирования микросомальной простагландин-e2-синтазы 1 | |
| EA201691442A1 (ru) | N-азаспироциклоалканзамещенные n-гетероарильные соединения и композиции для ингибирования активности shp2 | |
| EA201990019A1 (ru) | Соединения и композиции для подавления активности shp2 | |
| EA201892008A1 (ru) | Соединения и способы лечения неврологических и сердечно-сосудистых состояний | |
| EA201691070A1 (ru) | Новые трициклические соединения в качестве противораковых средств | |
| EA201790764A1 (ru) | Новые соединения карбоновых кислот, подходящие для ингибирования микросомальной простагландин-e2-синтазы 1 | |
| EA201591746A1 (ru) | Способы и композиции для ингибирования бромодомен-содержащих белков | |
| EA201790246A1 (ru) | Гетероциклические карбоновые кислоты в качестве активаторов растворимой гуанилатциклазы | |
| EA201990400A1 (ru) | Соединения и композиции и их применение | |
| EA201691272A1 (ru) | Тетрагидропиридопиразины в качестве модуляторов gpr6 | |
| EA201500298A1 (ru) | Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы | |
| EA201790599A1 (ru) | Соединения и композиции в качестве ингибиторов киназ | |
| EA201790745A1 (ru) | Трициклические соединения | |
| EA201792425A1 (ru) | Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз | |
| EA201790519A1 (ru) | Терапевтические соединения в качестве ингибиторов рецептора орексина-1 | |
| MX376283B (es) | Compuestos de imidazopiridazina. | |
| EA201890449A1 (ru) | Фумагиллиновые гетероциклические соединения и способы их получения и применения | |
| EA201590228A1 (ru) | Антагонисты 5-ht3 рецептора | |
| UY35625A (es) | Compuestos de tetrahidrocarbazol y carbazol carboxamida sustituidos como inhibidores de quinasa | |
| MX387443B (es) | Compuestos de heteroarilcarboxamida como inhibidores de ripk2 | |
| PH12017500810A1 (en) | Substituted 2,4 diamino-quinoline as new anticancer agents | |
| EA201690846A1 (ru) | Замещенные производные пиридина, пригодные в качестве ингибиторов gsk-3 | |
| EA201892726A1 (ru) | Дейтерированный палбоциклиб | |
| EA201691413A1 (ru) | Селективные антагонисты nr2b | |
| EA201790830A1 (ru) | Ингибиторы альдостеронсинтазы |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |